Compare Aurora Cannabis Inc (ACB) vs Fabrinet (FN) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

FN trades at $500.75, up 0.23% with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with 75% buy ratings and a $733 price target, representing 46% upside potential from current levels. Recent news highlights FN's strategic position in AI optical supply chain with capacity expansion supporting multi-year growth visibility.

The outlook remains positive driven by AI infrastructure demand and strong execution, though premium valuation metrics (P/E 43.02) and technical bearish signals warrant caution. Key risks include datacom supply constraints and FX volatility, but robust revenue growth projections ($4.2B for 2026) and expanding margins support the bullish analyst stance.